A 41-year-old white man presented with a 7-year history of erythematous papules, livedo reticularis, swelling, myalgias, arthralgias, Raynaud phenomenon, and very large, painful and progressive ulcers on the lower part of both legs (Figure 1) . A skin biopsy specimen revealed polyarteritis nodosa (PAN) with fibrinoid necrosis of medium-sized vessels. The patient fulfilled 4 of the criteria for PAN (ie, weight loss Ͼ4 kg, livedo reticularis, myalgias, and characteristic histological picture).
/L), and antinuclear antibody titer (1:640, speckled pattern). Systemic prednisone therapy administered at dosages as high as 100 mg/d had little, if any, effect. The patient's intense pain could only be controlled with morphine derivatives.
THERAPEUTIC CHALLENGE
Polyarteritis nodosa is a necrotizing vasculitis of small and medium-sized arteries with a chronic course that needs effective long-term treatment with a favorable benefit-risk ratio, and our patient failed to respond to prednisone treatment.
SOLUTION
Treatment consisting of intravenous injections of methotrexate (25 mg/wk) was initiated. The skin lesions improved and the patient's pain ceased, so the morphine treatment could be discontinued. The ulcers completely healed within 6 months. The methotrexate therapy was not discontinued, but the dosage was adjusted based on disease activity (range, 10-35 mg/wk). The initial remission lasted for 15 months, at which time the patient again developed ulcers on the lower part of both legs despite ongoing methotrexate therapy (10-25 mg/wk), but the ulcers were much smaller, less deep, and not as painful as they were before methotrexate therapy was begun. To achieve rehealing, the dosage was adjusted (25-35 mg/wk). After 13 months, all the new ulcers had completely disappeared, and after 7 months the patient remained free of ulcers at a dosage of less than 25 mg/wk (Figure 3) .
Routine laboratory parameters and lymphocyte subsets as determined by flow cytometry were regularly monitored once a week to once a month. Initially, the PANassociated leukocytosis decreased during methotrexate therapy ( Figure 2 ). Despite ongoing methotrexate treatment, the number of leukocytes increased after 18 months and was accompanied by worsening of the clinical picture ( Figure 2 ). The treatment neither induced patho- logic alterations of routine laboratory findings nor decreased circulating T-lymphocyte subsets. Histological examination of a liver biopsy specimen obtained after a cumulative methotrexate dose of 2.5 g revealed no hepatic abnormalities. An ultrasonogram of abdominal organs showed no hepatic fibrosis or cirrhosis. Dynamic hepatic scintigraphy after cumulative doses of 3.8 and 5.2 g revealed normal findings. With single weekly intravenous doses ranging from 10 to 35 mg, methotrexate therapy has controlled the patient's PAN for more than 56 months. Despite a total cumulative dose of 5.5 g, the therapy was well tolerated, and we did not find any methotrexate-associated adverse effects.
COMMENT
Methotrexate has been successfully used in the treatment of different types of vasculitides, eg, Wegener granulomatosis, 2 Takayasu arteritis, 3 and giant cell arteritis, 4 and has rarely been reported in patients with PAN. 5, 6 This article represents the first report of long-term low-dose methotrexate therapy in a case of severe cutaneous PAN.
There is evidence that an anti-inflammatory mechanism rather than immunosuppression is responsible for the effectiveness of the low-dose methotrexate regimen. 7 This theory is supported by the lack of immunocompetent cell depression, 8 which was confirmed in our case by the results of long-term monitoring of leukocytes and circulating T-cell subsets. The fact that a wide spectrum of vascular diseases, including PAN, demonstrate improvement during low-dose methotrexate therapy leads to the assumption that methotrexate may control a crucial inflammatory step or factor. Since the report of Segal et al, 9 one of the major effects of low-dose methotrexate therapy seems to be the inhibition of interleukin 1 (IL-l) activity without alteration of either IL-1 synthesis or IL-1 secretion, a finding that has been confirmed by other researchers. 10, 11 Previously, we demonstrated in an in vitro assay that methotrexate inhibited IL-1␤ binding to its cell surface receptor. 12 Interleukin 1 plays a central role in inflammatory events and vasculitides. It activates endothelial cells to express adhesion molecules and to produce other pro-inflammatory cytokines, such as IL-6 and IL-8, and stimulates the chemotactic activity of neutrophils. Moreover, methotrexate inhibits leukotriene B4-and/or C5a-induced neutrophil and macrophage chemotaxis 13 and reduces platelet activation factorinduced leukocyte-endothelial cell adhesion. 14 The case presented herein is interesting in several respects: (1) as has been established in cases of psoriasis and rheumatoid arthritis, our case shows that methotrexate therapy also has short-and long-term efficacy in PAN; (2) short-term treatment involves a low risk for the development of adverse effects, but even during longterm follow-up (Ͼ56 months) of methotrexate treatment, our patient did not develop immunosuppression or any other adverse reaction; and (3) disease activity runs in parallel with absolute peripheral blood leukocyte counts ( Figure 2 ). We presume that the clinical improvement noted was mediated by methotrexate's anti-inflammatory properties. Therefore, low-dose methotrexate therapy appears to represent an interesting alternative treatment strategy for managing this complex disease. Clinical trials will be necessary to confirm this observation in a larger group of patients. 
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